Q3 EPS Estimates for Haemonetics Decreased by Zacks Research

Haemonetics Co. (NYSE:HAE) – Stock analysts at Zacks Research lowered their Q3 2025 earnings per share estimates for shares of Haemonetics in a research note issued to investors on Wednesday, November 27th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will post earnings per share of $1.19 for the quarter, down from their prior forecast of $1.22. The consensus estimate for Haemonetics’ current full-year earnings is $4.59 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2025 earnings at $1.26 EPS, FY2025 earnings at $4.59 EPS, Q1 2026 earnings at $1.18 EPS, Q3 2026 earnings at $1.32 EPS, FY2026 earnings at $5.17 EPS and Q1 2027 earnings at $1.48 EPS.

A number of other equities research analysts also recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $112.00 target price on shares of Haemonetics in a report on Friday, November 15th. Barrington Research reissued an “outperform” rating and set a $108.00 target price on shares of Haemonetics in a research note on Friday, November 8th. CL King initiated coverage on shares of Haemonetics in a report on Friday, September 13th. They set a “buy” rating and a $116.00 price target on the stock. JMP Securities restated a “market outperform” rating and issued a $125.00 target price on shares of Haemonetics in a research report on Tuesday, August 13th. Finally, Bank of America started coverage on shares of Haemonetics in a research note on Wednesday, September 11th. They set a “neutral” rating and a $85.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Haemonetics has an average rating of “Moderate Buy” and an average target price of $107.88.

Haemonetics Stock Performance

NYSE HAE opened at $87.47 on Monday. The firm’s 50 day simple moving average is $79.99 and its 200 day simple moving average is $82.05. The firm has a market capitalization of $4.39 billion, a price-to-earnings ratio of 36.29, a P/E/G ratio of 1.36 and a beta of 0.32. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. Haemonetics has a 1 year low of $70.25 and a 1 year high of $97.97.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.03. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The business had revenue of $345.50 million during the quarter, compared to analysts’ expectations of $342.57 million. During the same quarter in the prior year, the business posted $0.99 earnings per share. Haemonetics’s revenue was up 8.6% compared to the same quarter last year.

Hedge Funds Weigh In On Haemonetics

Hedge funds have recently modified their holdings of the business. Wellington Management Group LLP increased its holdings in Haemonetics by 9.5% in the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock valued at $337,722,000 after purchasing an additional 363,702 shares during the period. Royce & Associates LP increased its stake in shares of Haemonetics by 2.6% in the third quarter. Royce & Associates LP now owns 1,210,546 shares of the medical instruments supplier’s stock valued at $97,304,000 after buying an additional 30,868 shares during the period. Geode Capital Management LLC raised its position in shares of Haemonetics by 1.8% during the third quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier’s stock worth $95,986,000 after acquiring an additional 21,547 shares during the last quarter. Thrivent Financial for Lutherans lifted its stake in shares of Haemonetics by 29.5% in the third quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock worth $88,433,000 after acquiring an additional 250,833 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Haemonetics by 6.3% in the second quarter. Dimensional Fund Advisors LP now owns 978,735 shares of the medical instruments supplier’s stock valued at $80,972,000 after acquiring an additional 57,665 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.